Genmab: Daratumumab is becoming an increasingly critical asset for JNJ

BUY-Top Picks, Fair Value DKK1170 (+39%)
News published on January Friday 29, 2016
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities